MPI for Heart and Lung Research
You are here: MPI HLR Home > Research > Department of Pharmacology > People > Current > Pharmacology

2016: Dieter-Klaus-Preis (ShengPeng Wang)
for his work on the identification of a new endothelial mechanisms of blood pressure control.

2016: Hermann-Rein-Preis (Boris Srilic)
for the discovery of a new mechanism mediating tumor cell metastasis.

2016: Rudi-Busse-Promotionspreis (Cong Tang)
for his thesis on loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes.

2015: Novartis Award for Therapy-relevant research (Nina Wettschureck)
for work on the role of GPCR HCA2 in mediating the beneficial effects of DMF in neuroinflammation (with H. Schwaninger, Lübeck).

2013: Rudolf-Buchheim Award (Dagmar Schumacher)
for her work on platelet-derived nucleotides in tumor cell transendothelial migration and metastsis.

2012: Galenus-von-Pergamon Award (Thomas Worzfeld)
for his work on plexin B1 on ErbB-2-expressing tumors.

2011: Otto-Hahn-Medaille (Kashan Ahmed)
for the discovery of a new receptor activated by lactate which plays an important role in the regulation of adipocyte lipolysis.

2011: Rudolf-Buchheim Award (Antonia Sassmann)
for her work on beta cell regulation through G-protein-mediated signaling.

Prof. Dr. Nina Wettschureck

Max Planck Institute for Heart and Lung Research
Department of Pharmacology
Ludwigstr. 43
61231 Bad Nauheim

Phone: +49 (0)6032 705 1214
Fax: +49 (0)6032 705 1204
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Curriculum Vitae

Since 2012                    Professor for Molecular Pharmacology, University of Frankfurt / Main

Since 2009                    Group Leader, Max-Planck-Institute for Heart and Lung Research Bad Nauheim.

2007                             "Habilitation" for Pharmacology and Toxicology, University of Heidelberg

2000 - 2009                   Postdoctoral Research Fellow, Institute of Pharmacology, University of Heidelberg

1998 – 2000                  Postdoctoral Research Fellow, Institute of Pharmacology, FU Berlin

1996 – 1998                  Dept. of Internal Medicine V, University of Heidelberg

1990 – 1996                  Studies of Medicine, M.D. degree, University of Frankfurt / Main, Germany


G-protein signaling group (Wettschureck group)

Group leader: Nina Wettschureck

Postdocs: Malarvizhi Gurusamy

PhD students: Jorge Carvalho, Jingchen Shao, Tianpeng Wang

Technical assistant: Martina Finkbeiner

Our group analyzes basic mechanisms of G-protein signaling in the cardiovascular and immune system. Using various in vitro techniques as well as conditional knockout mice, we identified new functions for the G-protein families G12/13 and Gq/11 in the regulation of immune cells (Herroeder et al., Immunity 2009; Grimm et al., ATVB 2016), endothelial cells (Sivaraj et al., Dev Cell 2013; Sivaraj et al., Cardiovasc Res 2015), endocrine cells (Sassmann et al., J Clin Invest 2010), and cardiomyocytes (Takefuji et al., Circulation 2012; Takefuji et al., J Exp Med 2013). We furthermore showed that the G-protein-coupled receptor HCA2 crucially contributes to the therapeutic effect of dimethyl fumarate in neuroinflammation (Chen et al., J Clin Invest 2014). Other ongoing projects focus on the mechanisms regulating cardiac fibroblast activation (Kaur et al., Circ Res 2016). New projects currently evolve based on single-cell expression analyses in primary murine vascular and immune cells (Kaur et al., Nat Commun 2017; Tischner et al., J Clin Invest Insight 2017). These analyses identified rare cell populations with specific GPCR repertoires; the role of these GPCRs in the regulation of smooth muscle differentiation, endothelial activation, or regulation of T cell pathogenicity is currently under investigation.

 Wettschureck group projects illustrated

Graphical overview of the topics addressed by the G-protein signaling group.

Selected references

1. Carvalho J, Chennupati R, Li R, Günther S, Kaur H, Zhao W, Tonack S, Kurz M, Mößlein N, Bünemann M, Offermanns S, Wettschureck N (2020). Orphan G-protein-coupled receptor GPRC5B controls smooth muscle contractility and differentiation by inhibiting prostacyclin receptor signaling. Circulation 141(14):1168-83.

2. Wettschureck N, Strilic B, Offermanns S (2019). Passing the Vascular Barrier: Endothelial Signaling Processes Controlling Extravasation. Physiol Rev 99(3):1467-1525.

3. Tischner D, Grimm M, Kaur H, Staudenraus D, Carvalho J, Looso M, Günther S, Wanke F, Moos S, Siller N, Breuer J, Schwab N, Zipp F, Waisman A, Kurschus FC, Offermanns S, Wettschureck N (2017): Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation. JCI Insight 3;2(15), doi: 10.1172.

4. Kaur H, Carvalho J, Looso M, Singh P, Chennupati R, Preussner J, Günther S, Albarrán-Juárez J, Tischner D, Classen S, Offermanns S, Wettschureck N (2017): Single-cell profiling reveals heterogeneity and functional patterning of GPCR expression in the vascular system. Nat Commun 8:15700; DOI: 10.1038.

5. Kaur H, Takefuji M, Ngai C, Carvalho J, Bayer J, Wietelmann A, Poetsch A, Holper S, Conway SJ, Mollmann H, Looso M, Troidl C, Offermanns S, Wettschureck N (2016): Targeted Ablation of Periostin-Expressing Activated Fibroblasts Prevents Adverse Cardiac Remodeling in Mice. Circ Res 118:1906-17.

6. Grimm M, Tischner D, Troidl K, Albarran Juarez J, Sivaraj KK, Ferreiros Bouzas N, Geisslinger G, Binder CJ, and Wettschureck N (2016): S1P2/G12/13 Signaling Negatively Regulates Macrophage Activation and Indirectly Shapes the Atheroprotective B1-Cell Population. Arterioscler Thromb Vasc Biol 36:37-48.

7. Sivaraj KK, Li R, Albarran-Juarez J, Wang S, Tischner D, Grimm M, Swiercz JM, Offermanns S, and Wettschureck N (2015): Endothelial Galphaq/11 is required for VEGF-induced vascular permeability and angiogenesis. Cardiovasc Res 108:171-80.

8. Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, Kohl J, Offermanns S, Wettschureck N*, and Schwaninger M* (2014): Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest 124:2188-92. (*contributed equally)

9. Sivaraj KK, Takefuji M, Schmidt I, Adams RH, Offermanns S, and Wettschureck N (2013): G13 controls angiogenesis through regulation of VEGFR-2 expression. Dev Cell 25:427-34.

10. Takefuji M, Kruger M, Sivaraj KK, Kaibuchi K, Offermanns S, and Wettschureck N (2013): RhoGEF12 controls cardiac remodeling by integrating G protein- and integrin-dependent signaling cascades. J Exp Med 210:665-73.

11. Takefuji M, Wirth A, Lukasova M, Takefuji S, Boettger T, Braun T, Althoff T, Offermanns S, and Wettschureck N (2012): G13-mediated signaling pathway is required for pressure overload-induced cardiac remodeling and heart failure. Circulation 126:1972-82.

12. Sassmann A, Gier B, Grone HJ, Drews G, Offermanns S, and Wettschureck N (2010): The Gq/G11-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in mice. J Clin Invest 120:2184-93.

13. Herroeder S, Reichardt P, Sassmann A, Zimmermann B, Jaeneke D, Hoeckner J, Hollmann MW, Fischer KD, Vogt S, Grosse R, Hogg N, Gunzer M, Offermanns S, Wettschureck N (2009): Guanine nucleotide-binding proteins of the G12 family shape immune functions by controlling CD4+ T cell adhesiveness and motility. Immunity 30:708-20.




Prof. Dr. Stefan Offermanns
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone:  +49 (0)6032 705 1201

Prof. Dr. Thomas Worzfeld

Pharmakologisches Institut
der Phillips-Universität Marburg
K|03 Biochemisch-Pharmakologisches Centrum (Raum: +3/1220)
Karl-von-Frisch-Straße 2
35032 Marburg

Phone: +49 (0)6421 28-65001
Fax: +49 (0)6421 28-65600
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.


--> Research


--> Members


--> Publications

Die nachstehenden Informationen enthalten die gesetzlich vorgesehenen Pflichtangaben zur Anbieterkennzeichnung sowie wichtige rechtliche Hinweise zur Internetpräsenz des Max-Planck-Instituts für Herz- und Lungenforschung (


Anbieter dieser Internetpräsenz ist im Rechtssinne die
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.


zur Förderung der Wissenschaften e.V.
Hofgartenstraße 8
80539 München
Telefon: +49 (89) 2108 - 0


Die Max-Planck-Gesellschaft ist im Vereinsregister des Amtsgerichts Berlin-Charlottenburg unter der Registernummer VR 13378 B eingetragen.


Die Max-Planck-Gesellschaft wird gesetzlich vertreten durch den Vereinsvorstand, und dieser wiederum durch den Präsidenten, Prof. Dr. Martin Stratmann, und den Generalsekretär, Herrn Rüdiger Willems.


Die Umsatzsteueridentifikationsnummer der Max-Planck-Gesellschaft lautet:
DE 129517720

Redaktionsverantwortlich für die Internetpräsenz der Abteilung II: Pharmakologie des Max-Planck-Instituts für Herz- und Lungenforschung i. S. d. P.

Frau Svea Hümmer (Sekretariat Abt. II: Pharmakologie)


Rechtliche Hinweise zur Organisationsform

Die Max-Planck-Gesellschaft ist eine gemeinnützige Forschungseinrichtung, die in der Rechtsform eines eingetragenen Vereins organisiert ist. Die Institute und Einrichtungen der Max-Planck-Gesellschaft sind organisatorisch weitgehend selbständig und haben in der Regel keine eigene Rechtspersönlichkeit.

Visuelles Erscheinungsbild

Konzept und Gestaltung: EDVAS

Programmierung: Alexander Schmidt auf Joomla!